Susanne R Youngren-Ortiz1, David B Hill2,3, Peter R Hoffmann4, Kenneth R Morris1,5, Edward G Barrett6, M Gregory Forest7, Mahavir B Chougule1,8,9,10. 1. 1 Translational Drug Delivery Research (TransDDR) Laboratory, Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawai'i at Hilo , Hilo, Hawai'i. 2. 2 Department of Physics and Astronomy, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina. 3. 3 Marsico Lung Institute/CF Center, The University of North Carolina School of Medicine , Chapel Hill, North Carolina. 4. 4 Department of Cell and Molecular Biology, John A. Burns School of Medicine, University of Hawai'i , Honolulu, Hawai'i. 5. 5 The Lachman Institute for Pharmaceutical Analysis, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University-Brooklyn Campus , Brooklyn, New York. 6. 6 Respiratory and Asthma Program, Lovelace Respiratory Research Institute , Albuquerque, New Mexico. 7. 7 Carolina Center for Interdisciplinary Applied Mathematics, The University of North Carolina at Chapel Hill , Chapel Hill, North Carolina. 8. 8 Pii Center for Pharmaceutical Technology, Research Institute of Pharmaceutical Sciences, University of Mississippi , Oxford, Mississippi. 9. 9 Translational Drug and Gene Delivery Research (TransDGDR) Laboratory, Department of Pharmaceutics and Drug Delivery, School of Pharmacy, University of Mississippi , Oxford, Mississippi. 10. 10 Natural Products and Experimental Therapeutics Program, University of Hawai'i Cancer Center, University of Hawai'i , Honolulu, Hawai'i.
Abstract
BACKGROUND: Aerosol delivery of chemotherapeutic nanocarriers represents a promising alternative for lung cancer therapy. This study optimized gemcitabine (Gem)-loaded gelatin nanocarriers (GNCs) cross-linked with genipin (Gem-GNCs) to evaluate their potential for nebulized lung cancer treatment. METHODS: Gem-GNCs were prepared by two-step desolvation and optimized through Taguchi design and characterized for physicochemical properties. Particle size and morphology were confirmed by scanning and transmission electron microscopy. In vitro release of Gem from Gem-GNCs performed in Dulbecco's phosphate-buffered saline and simulated lung fluid was evaluated to determine release mechanisms. Particle size stability was assessed under varying pH. Differential scanning calorimetry and powder X-ray diffraction were used to determine the presence and stability of Gem-GNC components and amorphization of Gem, respectively. Gem-GNC efficacy within A549 and H460 cells was evaluated using MTT assays. Mucus rheology upon treatment with Gem-GNCs, lactose, and normal saline control was measured. Andersen cascade impaction identified the aerodynamic particle size distribution of the nebulized formulation. RESULTS: Gem-GNCs had particle size, zeta potential, entrapment efficiency, and loading efficiency of 178 ± 7.1 nm, -18.9 mV, 92.5%, and 9.1%, respectively. The Gem and formulation excipients where molecularly dispersed and configured amorphously. Gem-GNCs were stable at pH 5.4-7.4 for 72 hours. Gem release from Gem-GNCs was governed by non-Fickian controlled release due to diffusion/erosion from a matrix-based nanocarrier. Gem-GNCs elicited a 40% reduction of the complex viscosity η*(1 Hz) of human bronchial epithelial cell mucus containing 3 wt% solids to mimic mild airway disease. The nebulized Gem-GNCs had a mass median aerodynamic diameter (MMAD) of 2.0 ± 0.16 μm, geometric standard deviation (GSD) of 2.7 ± 0.16, and fine particle fraction (FPF) of 75.2% ± 2.4%. The Gem-GNC formulation did not outperform the Gem solution in A549 cells. However, in H460, Gem-GNCs outperformed the Gem IC50 reduction by ∼5-fold at 48 and 10-fold 72 hours. CONCLUSION: Stable, effective, and sustained-release Gem-GNCs were developed. The nebulized Gem-GNCs had satisfactory MMAD, GSD, and FPF and the formulation reduced the dynamic complex viscosity of mucus consistent with increased mobility of nanoparticles.
BACKGROUND: Aerosol delivery of chemotherapeutic nanocarriers represents a promising alternative for lung cancer therapy. This study optimized gemcitabine (Gem)-loaded gelatin nanocarriers (GNCs) cross-linked with genipin (Gem-GNCs) to evaluate their potential for nebulized lung cancer treatment. METHODS:Gem-GNCs were prepared by two-step desolvation and optimized through Taguchi design and characterized for physicochemical properties. Particle size and morphology were confirmed by scanning and transmission electron microscopy. In vitro release of Gem from Gem-GNCs performed in Dulbecco'sphosphate-buffered saline and simulated lung fluid was evaluated to determine release mechanisms. Particle size stability was assessed under varying pH. Differential scanning calorimetry and powder X-ray diffraction were used to determine the presence and stability of Gem-GNC components and amorphization of Gem, respectively. Gem-GNC efficacy within A549 and H460 cells was evaluated using MTT assays. Mucus rheology upon treatment with Gem-GNCs, lactose, and normal saline control was measured. Andersen cascade impaction identified the aerodynamic particle size distribution of the nebulized formulation. RESULTS:Gem-GNCs had particle size, zeta potential, entrapment efficiency, and loading efficiency of 178 ± 7.1 nm, -18.9 mV, 92.5%, and 9.1%, respectively. The Gem and formulation excipients where molecularly dispersed and configured amorphously. Gem-GNCs were stable at pH 5.4-7.4 for 72 hours. Gem release from Gem-GNCs was governed by non-Fickian controlled release due to diffusion/erosion from a matrix-based nanocarrier. Gem-GNCs elicited a 40% reduction of the complex viscosity η*(1 Hz) of human bronchial epithelial cell mucus containing 3 wt% solids to mimic mild airway disease. The nebulized Gem-GNCs had a mass median aerodynamic diameter (MMAD) of 2.0 ± 0.16 μm, geometric standard deviation (GSD) of 2.7 ± 0.16, and fine particle fraction (FPF) of 75.2% ± 2.4%. The Gem-GNC formulation did not outperform the Gem solution in A549 cells. However, in H460, Gem-GNCs outperformed the Gem IC50 reduction by ∼5-fold at 48 and 10-fold 72 hours. CONCLUSION: Stable, effective, and sustained-release Gem-GNCs were developed. The nebulized Gem-GNCs had satisfactory MMAD, GSD, and FPF and the formulation reduced the dynamic complex viscosity of mucus consistent with increased mobility of nanoparticles.
Authors: Ami Teague Deaton; LaTarsha D Jones; Craig A Dunbar; Anthony J Hickey; Dennis M Williams Journal: Pharm Dev Technol Date: 2002-05 Impact factor: 3.133
Authors: Itishri Sahu; A K M Ashiqul Haque; Brian Weidensee; Petra Weinmann; Michael S D Kormann Journal: Mol Ther Date: 2019-03-06 Impact factor: 11.454
Authors: Rasha S Elbatanony; Vineela Parvathaneni; Nishant S Kulkarni; Snehal K Shukla; Gautam Chauhan; Nitesh K Kunda; Vivek Gupta Journal: Drug Deliv Transl Res Date: 2021-06 Impact factor: 5.671